nodes	percent_of_prediction	percent_of_DWPC	metapath
Glycopyrrolate—Nasal congestion—Cisplatin—bone cancer	0.0108	0.0108	CcSEcCtD
Glycopyrrolate—Anaphylactoid reaction—Cisplatin—bone cancer	0.0102	0.0102	CcSEcCtD
Glycopyrrolate—Nystagmus—Epirubicin—bone cancer	0.00978	0.00978	CcSEcCtD
Glycopyrrolate—Irritability—Cisplatin—bone cancer	0.00943	0.00943	CcSEcCtD
Glycopyrrolate—Dehydration—Cisplatin—bone cancer	0.00918	0.00918	CcSEcCtD
Glycopyrrolate—Nystagmus—Doxorubicin—bone cancer	0.00905	0.00905	CcSEcCtD
Glycopyrrolate—Nasopharyngitis—Cisplatin—bone cancer	0.00883	0.00883	CcSEcCtD
Glycopyrrolate—Ageusia—Epirubicin—bone cancer	0.00862	0.00862	CcSEcCtD
Glycopyrrolate—Abdominal discomfort—Cisplatin—bone cancer	0.00818	0.00818	CcSEcCtD
Glycopyrrolate—Ageusia—Doxorubicin—bone cancer	0.00798	0.00798	CcSEcCtD
Glycopyrrolate—Cystitis noninfective—Methotrexate—bone cancer	0.00729	0.00729	CcSEcCtD
Glycopyrrolate—Cystitis—Methotrexate—bone cancer	0.00721	0.00721	CcSEcCtD
Glycopyrrolate—Atrioventricular block—Epirubicin—bone cancer	0.0072	0.0072	CcSEcCtD
Glycopyrrolate—Ventricular tachycardia—Epirubicin—bone cancer	0.00699	0.00699	CcSEcCtD
Glycopyrrolate—Injection site reaction—Epirubicin—bone cancer	0.00695	0.00695	CcSEcCtD
Glycopyrrolate—Cystitis noninfective—Epirubicin—bone cancer	0.00682	0.00682	CcSEcCtD
Glycopyrrolate—Bladder pain—Methotrexate—bone cancer	0.00675	0.00675	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Cisplatin—bone cancer	0.00675	0.00675	CcSEcCtD
Glycopyrrolate—Cystitis—Epirubicin—bone cancer	0.00675	0.00675	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Cisplatin—bone cancer	0.00671	0.00671	CcSEcCtD
Glycopyrrolate—Urethral disorder—Cisplatin—bone cancer	0.0067	0.0067	CcSEcCtD
Glycopyrrolate—Atrioventricular block—Doxorubicin—bone cancer	0.00666	0.00666	CcSEcCtD
Glycopyrrolate—Ventricular tachycardia—Doxorubicin—bone cancer	0.00647	0.00647	CcSEcCtD
Glycopyrrolate—Injection site reaction—Doxorubicin—bone cancer	0.00643	0.00643	CcSEcCtD
Glycopyrrolate—Flushing—Cisplatin—bone cancer	0.00634	0.00634	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Cisplatin—bone cancer	0.00634	0.00634	CcSEcCtD
Glycopyrrolate—Bladder pain—Epirubicin—bone cancer	0.00632	0.00632	CcSEcCtD
Glycopyrrolate—Cystitis noninfective—Doxorubicin—bone cancer	0.00631	0.00631	CcSEcCtD
Glycopyrrolate—Cystitis—Doxorubicin—bone cancer	0.00624	0.00624	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Cisplatin—bone cancer	0.00616	0.00616	CcSEcCtD
Glycopyrrolate—Erythema—Cisplatin—bone cancer	0.00595	0.00595	CcSEcCtD
Glycopyrrolate—Malnutrition—Cisplatin—bone cancer	0.00595	0.00595	CcSEcCtD
Glycopyrrolate—Flatulence—Cisplatin—bone cancer	0.00586	0.00586	CcSEcCtD
Glycopyrrolate—Bladder pain—Doxorubicin—bone cancer	0.00585	0.00585	CcSEcCtD
Glycopyrrolate—Vision blurred—Cisplatin—bone cancer	0.00561	0.00561	CcSEcCtD
Glycopyrrolate—Anaphylactoid reaction—Methotrexate—bone cancer	0.0056	0.0056	CcSEcCtD
Glycopyrrolate—Anaphylactoid reaction—Epirubicin—bone cancer	0.00524	0.00524	CcSEcCtD
Glycopyrrolate—Irritability—Methotrexate—bone cancer	0.00517	0.00517	CcSEcCtD
Glycopyrrolate—Convulsion—Cisplatin—bone cancer	0.00515	0.00515	CcSEcCtD
Glycopyrrolate—Mood swings—Methotrexate—bone cancer	0.00513	0.00513	CcSEcCtD
Glycopyrrolate—Pain in extremity—Epirubicin—bone cancer	0.00507	0.00507	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00503	0.00503	CcSEcCtD
Glycopyrrolate—Affect lability—Epirubicin—bone cancer	0.00499	0.00499	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Cisplatin—bone cancer	0.00485	0.00485	CcSEcCtD
Glycopyrrolate—Oedema—Cisplatin—bone cancer	0.00485	0.00485	CcSEcCtD
Glycopyrrolate—Anaphylactoid reaction—Doxorubicin—bone cancer	0.00485	0.00485	CcSEcCtD
Glycopyrrolate—Cardiac arrest—Epirubicin—bone cancer	0.00482	0.00482	CcSEcCtD
Glycopyrrolate—Infection—Cisplatin—bone cancer	0.00482	0.00482	CcSEcCtD
Glycopyrrolate—Mood swings—Epirubicin—bone cancer	0.0048	0.0048	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Cisplatin—bone cancer	0.00476	0.00476	CcSEcCtD
Glycopyrrolate—Tachycardia—Cisplatin—bone cancer	0.00474	0.00474	CcSEcCtD
Glycopyrrolate—Dehydration—Epirubicin—bone cancer	0.00472	0.00472	CcSEcCtD
Glycopyrrolate—Skin disorder—Cisplatin—bone cancer	0.00472	0.00472	CcSEcCtD
Glycopyrrolate—Pain in extremity—Doxorubicin—bone cancer	0.00469	0.00469	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Cisplatin—bone cancer	0.00469	0.00469	CcSEcCtD
Glycopyrrolate—Dry skin—Epirubicin—bone cancer	0.00465	0.00465	CcSEcCtD
Glycopyrrolate—Affect lability—Doxorubicin—bone cancer	0.00462	0.00462	CcSEcCtD
Glycopyrrolate—Hypotension—Cisplatin—bone cancer	0.00454	0.00454	CcSEcCtD
Glycopyrrolate—Nasopharyngitis—Epirubicin—bone cancer	0.00454	0.00454	CcSEcCtD
Glycopyrrolate—Abdominal discomfort—Methotrexate—bone cancer	0.00449	0.00449	CcSEcCtD
Glycopyrrolate—Cardiac arrest—Doxorubicin—bone cancer	0.00446	0.00446	CcSEcCtD
Glycopyrrolate—Mood swings—Doxorubicin—bone cancer	0.00445	0.00445	CcSEcCtD
Glycopyrrolate—Abdominal distension—Epirubicin—bone cancer	0.00441	0.00441	CcSEcCtD
Glycopyrrolate—Dysuria—Methotrexate—bone cancer	0.00438	0.00438	CcSEcCtD
Glycopyrrolate—Dehydration—Doxorubicin—bone cancer	0.00436	0.00436	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Methotrexate—bone cancer	0.00435	0.00435	CcSEcCtD
Glycopyrrolate—Erectile dysfunction—Methotrexate—bone cancer	0.00431	0.00431	CcSEcCtD
Glycopyrrolate—Dry skin—Doxorubicin—bone cancer	0.0043	0.0043	CcSEcCtD
Glycopyrrolate—Pneumonia—Methotrexate—bone cancer	0.0042	0.0042	CcSEcCtD
Glycopyrrolate—Nasopharyngitis—Doxorubicin—bone cancer	0.0042	0.0042	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Cisplatin—bone cancer	0.00419	0.00419	CcSEcCtD
Glycopyrrolate—Infestation—Methotrexate—bone cancer	0.00418	0.00418	CcSEcCtD
Glycopyrrolate—Drowsiness—Methotrexate—bone cancer	0.00418	0.00418	CcSEcCtD
Glycopyrrolate—Infestation NOS—Methotrexate—bone cancer	0.00418	0.00418	CcSEcCtD
Glycopyrrolate—Pain—Cisplatin—bone cancer	0.00415	0.00415	CcSEcCtD
Glycopyrrolate—Dysuria—Epirubicin—bone cancer	0.0041	0.0041	CcSEcCtD
Glycopyrrolate—Abdominal distension—Doxorubicin—bone cancer	0.00408	0.00408	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Epirubicin—bone cancer	0.00407	0.00407	CcSEcCtD
Glycopyrrolate—Sweating—Methotrexate—bone cancer	0.004	0.004	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Cisplatin—bone cancer	0.004	0.004	CcSEcCtD
Glycopyrrolate—Hyperglycaemia—Epirubicin—bone cancer	0.00395	0.00395	CcSEcCtD
Glycopyrrolate—Epistaxis—Methotrexate—bone cancer	0.00394	0.00394	CcSEcCtD
Glycopyrrolate—Pneumonia—Epirubicin—bone cancer	0.00393	0.00393	CcSEcCtD
Glycopyrrolate—Infestation NOS—Epirubicin—bone cancer	0.00391	0.00391	CcSEcCtD
Glycopyrrolate—Infestation—Epirubicin—bone cancer	0.00391	0.00391	CcSEcCtD
Glycopyrrolate—Drowsiness—Epirubicin—bone cancer	0.00391	0.00391	CcSEcCtD
Glycopyrrolate—Body temperature increased—Cisplatin—bone cancer	0.00384	0.00384	CcSEcCtD
Glycopyrrolate—Urinary tract infection—Epirubicin—bone cancer	0.0038	0.0038	CcSEcCtD
Glycopyrrolate—Dysuria—Doxorubicin—bone cancer	0.00379	0.00379	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Doxorubicin—bone cancer	0.00377	0.00377	CcSEcCtD
Glycopyrrolate—Sweating—Epirubicin—bone cancer	0.00375	0.00375	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Methotrexate—bone cancer	0.0037	0.0037	CcSEcCtD
Glycopyrrolate—Epistaxis—Epirubicin—bone cancer	0.00369	0.00369	CcSEcCtD
Glycopyrrolate—Urethral disorder—Methotrexate—bone cancer	0.00368	0.00368	CcSEcCtD
Glycopyrrolate—Sinusitis—Epirubicin—bone cancer	0.00367	0.00367	CcSEcCtD
Glycopyrrolate—Hyperglycaemia—Doxorubicin—bone cancer	0.00366	0.00366	CcSEcCtD
Glycopyrrolate—Pneumonia—Doxorubicin—bone cancer	0.00364	0.00364	CcSEcCtD
Glycopyrrolate—Infestation NOS—Doxorubicin—bone cancer	0.00362	0.00362	CcSEcCtD
Glycopyrrolate—Infestation—Doxorubicin—bone cancer	0.00362	0.00362	CcSEcCtD
Glycopyrrolate—Drowsiness—Doxorubicin—bone cancer	0.00362	0.00362	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Cisplatin—bone cancer	0.00358	0.00358	CcSEcCtD
Glycopyrrolate—Rhinitis—Epirubicin—bone cancer	0.00352	0.00352	CcSEcCtD
Glycopyrrolate—Urinary tract infection—Doxorubicin—bone cancer	0.00352	0.00352	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Epirubicin—bone cancer	0.00349	0.00349	CcSEcCtD
Glycopyrrolate—Asthenia—Cisplatin—bone cancer	0.00348	0.00348	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Methotrexate—bone cancer	0.00348	0.00348	CcSEcCtD
Glycopyrrolate—Sweating—Doxorubicin—bone cancer	0.00347	0.00347	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Epirubicin—bone cancer	0.00347	0.00347	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Epirubicin—bone cancer	0.00345	0.00345	CcSEcCtD
Glycopyrrolate—Urethral disorder—Epirubicin—bone cancer	0.00344	0.00344	CcSEcCtD
Glycopyrrolate—Epistaxis—Doxorubicin—bone cancer	0.00341	0.00341	CcSEcCtD
Glycopyrrolate—Sinusitis—Doxorubicin—bone cancer	0.00339	0.00339	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Methotrexate—bone cancer	0.00338	0.00338	CcSEcCtD
Glycopyrrolate—Mental disorder—Methotrexate—bone cancer	0.00328	0.00328	CcSEcCtD
Glycopyrrolate—Erythema—Methotrexate—bone cancer	0.00326	0.00326	CcSEcCtD
Glycopyrrolate—Malnutrition—Methotrexate—bone cancer	0.00326	0.00326	CcSEcCtD
Glycopyrrolate—Flushing—Epirubicin—bone cancer	0.00326	0.00326	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Epirubicin—bone cancer	0.00326	0.00326	CcSEcCtD
Glycopyrrolate—Rhinitis—Doxorubicin—bone cancer	0.00325	0.00325	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Doxorubicin—bone cancer	0.00323	0.00323	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Doxorubicin—bone cancer	0.00321	0.00321	CcSEcCtD
Glycopyrrolate—Dysgeusia—Methotrexate—bone cancer	0.0032	0.0032	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Doxorubicin—bone cancer	0.00319	0.00319	CcSEcCtD
Glycopyrrolate—Urethral disorder—Doxorubicin—bone cancer	0.00318	0.00318	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Epirubicin—bone cancer	0.00316	0.00316	CcSEcCtD
Glycopyrrolate—Vomiting—Cisplatin—bone cancer	0.00309	0.00309	CcSEcCtD
Glycopyrrolate—Vision blurred—Methotrexate—bone cancer	0.00308	0.00308	CcSEcCtD
Glycopyrrolate—Mental disorder—Epirubicin—bone cancer	0.00307	0.00307	CcSEcCtD
Glycopyrrolate—Rash—Cisplatin—bone cancer	0.00306	0.00306	CcSEcCtD
Glycopyrrolate—Dermatitis—Cisplatin—bone cancer	0.00306	0.00306	CcSEcCtD
Glycopyrrolate—Erythema—Epirubicin—bone cancer	0.00305	0.00305	CcSEcCtD
Glycopyrrolate—Malnutrition—Epirubicin—bone cancer	0.00305	0.00305	CcSEcCtD
Glycopyrrolate—Flushing—Doxorubicin—bone cancer	0.00301	0.00301	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Doxorubicin—bone cancer	0.00301	0.00301	CcSEcCtD
Glycopyrrolate—Flatulence—Epirubicin—bone cancer	0.00301	0.00301	CcSEcCtD
Glycopyrrolate—Tension—Epirubicin—bone cancer	0.003	0.003	CcSEcCtD
Glycopyrrolate—Dysgeusia—Epirubicin—bone cancer	0.00299	0.00299	CcSEcCtD
Glycopyrrolate—Nervousness—Epirubicin—bone cancer	0.00297	0.00297	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Doxorubicin—bone cancer	0.00293	0.00293	CcSEcCtD
Glycopyrrolate—Nausea—Cisplatin—bone cancer	0.00288	0.00288	CcSEcCtD
Glycopyrrolate—Vision blurred—Epirubicin—bone cancer	0.00288	0.00288	CcSEcCtD
Glycopyrrolate—Mental disorder—Doxorubicin—bone cancer	0.00284	0.00284	CcSEcCtD
Glycopyrrolate—Convulsion—Methotrexate—bone cancer	0.00283	0.00283	CcSEcCtD
Glycopyrrolate—Malnutrition—Doxorubicin—bone cancer	0.00283	0.00283	CcSEcCtD
Glycopyrrolate—Erythema—Doxorubicin—bone cancer	0.00283	0.00283	CcSEcCtD
Glycopyrrolate—Agitation—Epirubicin—bone cancer	0.00281	0.00281	CcSEcCtD
Glycopyrrolate—Flatulence—Doxorubicin—bone cancer	0.00278	0.00278	CcSEcCtD
Glycopyrrolate—Tension—Doxorubicin—bone cancer	0.00277	0.00277	CcSEcCtD
Glycopyrrolate—Dysgeusia—Doxorubicin—bone cancer	0.00277	0.00277	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00276	0.00276	CcSEcCtD
Glycopyrrolate—Nervousness—Doxorubicin—bone cancer	0.00274	0.00274	CcSEcCtD
Glycopyrrolate—Palpitations—Epirubicin—bone cancer	0.0027	0.0027	CcSEcCtD
Glycopyrrolate—Confusional state—Methotrexate—bone cancer	0.00269	0.00269	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Methotrexate—bone cancer	0.00266	0.00266	CcSEcCtD
Glycopyrrolate—Vision blurred—Doxorubicin—bone cancer	0.00266	0.00266	CcSEcCtD
Glycopyrrolate—Convulsion—Epirubicin—bone cancer	0.00265	0.00265	CcSEcCtD
Glycopyrrolate—Infection—Methotrexate—bone cancer	0.00265	0.00265	CcSEcCtD
Glycopyrrolate—Hypertension—Epirubicin—bone cancer	0.00264	0.00264	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Methotrexate—bone cancer	0.00261	0.00261	CcSEcCtD
Glycopyrrolate—Agitation—Doxorubicin—bone cancer	0.0026	0.0026	CcSEcCtD
Glycopyrrolate—Skin disorder—Methotrexate—bone cancer	0.00259	0.00259	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00258	0.00258	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Methotrexate—bone cancer	0.00258	0.00258	CcSEcCtD
Glycopyrrolate—Dry mouth—Epirubicin—bone cancer	0.00254	0.00254	CcSEcCtD
Glycopyrrolate—Confusional state—Epirubicin—bone cancer	0.00251	0.00251	CcSEcCtD
Glycopyrrolate—Palpitations—Doxorubicin—bone cancer	0.0025	0.0025	CcSEcCtD
Glycopyrrolate—Oedema—Epirubicin—bone cancer	0.00249	0.00249	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Epirubicin—bone cancer	0.00249	0.00249	CcSEcCtD
Glycopyrrolate—Hypotension—Methotrexate—bone cancer	0.00249	0.00249	CcSEcCtD
Glycopyrrolate—Infection—Epirubicin—bone cancer	0.00248	0.00248	CcSEcCtD
Glycopyrrolate—Convulsion—Doxorubicin—bone cancer	0.00245	0.00245	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Epirubicin—bone cancer	0.00244	0.00244	CcSEcCtD
Glycopyrrolate—Hypertension—Doxorubicin—bone cancer	0.00244	0.00244	CcSEcCtD
Glycopyrrolate—Tachycardia—Epirubicin—bone cancer	0.00243	0.00243	CcSEcCtD
Glycopyrrolate—Skin disorder—Epirubicin—bone cancer	0.00242	0.00242	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Epirubicin—bone cancer	0.00241	0.00241	CcSEcCtD
Glycopyrrolate—Insomnia—Methotrexate—bone cancer	0.00241	0.00241	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00239	0.00239	CcSEcCtD
Glycopyrrolate—Somnolence—Methotrexate—bone cancer	0.00237	0.00237	CcSEcCtD
Glycopyrrolate—Dry mouth—Doxorubicin—bone cancer	0.00235	0.00235	CcSEcCtD
Glycopyrrolate—Dyspepsia—Methotrexate—bone cancer	0.00234	0.00234	CcSEcCtD
Glycopyrrolate—Hypotension—Epirubicin—bone cancer	0.00233	0.00233	CcSEcCtD
Glycopyrrolate—Confusional state—Doxorubicin—bone cancer	0.00233	0.00233	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Doxorubicin—bone cancer	0.00231	0.00231	CcSEcCtD
Glycopyrrolate—Oedema—Doxorubicin—bone cancer	0.00231	0.00231	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Methotrexate—bone cancer	0.0023	0.0023	CcSEcCtD
Glycopyrrolate—Fatigue—Methotrexate—bone cancer	0.0023	0.0023	CcSEcCtD
Glycopyrrolate—Infection—Doxorubicin—bone cancer	0.00229	0.00229	CcSEcCtD
Glycopyrrolate—Pain—Methotrexate—bone cancer	0.00228	0.00228	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Doxorubicin—bone cancer	0.00226	0.00226	CcSEcCtD
Glycopyrrolate—Insomnia—Epirubicin—bone cancer	0.00225	0.00225	CcSEcCtD
Glycopyrrolate—Tachycardia—Doxorubicin—bone cancer	0.00225	0.00225	CcSEcCtD
Glycopyrrolate—Skin disorder—Doxorubicin—bone cancer	0.00224	0.00224	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Doxorubicin—bone cancer	0.00223	0.00223	CcSEcCtD
Glycopyrrolate—Somnolence—Epirubicin—bone cancer	0.00222	0.00222	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Methotrexate—bone cancer	0.0022	0.0022	CcSEcCtD
Glycopyrrolate—Dyspepsia—Epirubicin—bone cancer	0.00219	0.00219	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Methotrexate—bone cancer	0.00218	0.00218	CcSEcCtD
Glycopyrrolate—Hypotension—Doxorubicin—bone cancer	0.00216	0.00216	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Epirubicin—bone cancer	0.00215	0.00215	CcSEcCtD
Glycopyrrolate—Fatigue—Epirubicin—bone cancer	0.00215	0.00215	CcSEcCtD
Glycopyrrolate—Constipation—Epirubicin—bone cancer	0.00213	0.00213	CcSEcCtD
Glycopyrrolate—Pain—Epirubicin—bone cancer	0.00213	0.00213	CcSEcCtD
Glycopyrrolate—Urticaria—Methotrexate—bone cancer	0.00212	0.00212	CcSEcCtD
Glycopyrrolate—Abdominal pain—Methotrexate—bone cancer	0.00211	0.00211	CcSEcCtD
Glycopyrrolate—Body temperature increased—Methotrexate—bone cancer	0.00211	0.00211	CcSEcCtD
Glycopyrrolate—Insomnia—Doxorubicin—bone cancer	0.00209	0.00209	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Epirubicin—bone cancer	0.00205	0.00205	CcSEcCtD
Glycopyrrolate—Somnolence—Doxorubicin—bone cancer	0.00205	0.00205	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Epirubicin—bone cancer	0.00204	0.00204	CcSEcCtD
Glycopyrrolate—Dyspepsia—Doxorubicin—bone cancer	0.00203	0.00203	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Doxorubicin—bone cancer	0.00199	0.00199	CcSEcCtD
Glycopyrrolate—Fatigue—Doxorubicin—bone cancer	0.00199	0.00199	CcSEcCtD
Glycopyrrolate—Urticaria—Epirubicin—bone cancer	0.00198	0.00198	CcSEcCtD
Glycopyrrolate—Pain—Doxorubicin—bone cancer	0.00197	0.00197	CcSEcCtD
Glycopyrrolate—Constipation—Doxorubicin—bone cancer	0.00197	0.00197	CcSEcCtD
Glycopyrrolate—Body temperature increased—Epirubicin—bone cancer	0.00197	0.00197	CcSEcCtD
Glycopyrrolate—Abdominal pain—Epirubicin—bone cancer	0.00197	0.00197	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Methotrexate—bone cancer	0.00196	0.00196	CcSEcCtD
Glycopyrrolate—Asthenia—Methotrexate—bone cancer	0.00191	0.00191	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Doxorubicin—bone cancer	0.0019	0.0019	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Doxorubicin—bone cancer	0.00189	0.00189	CcSEcCtD
Glycopyrrolate—Pruritus—Methotrexate—bone cancer	0.00188	0.00188	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Epirubicin—bone cancer	0.00184	0.00184	CcSEcCtD
Glycopyrrolate—Urticaria—Doxorubicin—bone cancer	0.00183	0.00183	CcSEcCtD
Glycopyrrolate—Body temperature increased—Doxorubicin—bone cancer	0.00182	0.00182	CcSEcCtD
Glycopyrrolate—Abdominal pain—Doxorubicin—bone cancer	0.00182	0.00182	CcSEcCtD
Glycopyrrolate—Asthenia—Epirubicin—bone cancer	0.00179	0.00179	CcSEcCtD
Glycopyrrolate—Pruritus—Epirubicin—bone cancer	0.00176	0.00176	CcSEcCtD
Glycopyrrolate—Dizziness—Methotrexate—bone cancer	0.00176	0.00176	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Doxorubicin—bone cancer	0.0017	0.0017	CcSEcCtD
Glycopyrrolate—Vomiting—Methotrexate—bone cancer	0.00169	0.00169	CcSEcCtD
Glycopyrrolate—Rash—Methotrexate—bone cancer	0.00168	0.00168	CcSEcCtD
Glycopyrrolate—Dermatitis—Methotrexate—bone cancer	0.00168	0.00168	CcSEcCtD
Glycopyrrolate—Headache—Methotrexate—bone cancer	0.00167	0.00167	CcSEcCtD
Glycopyrrolate—Asthenia—Doxorubicin—bone cancer	0.00165	0.00165	CcSEcCtD
Glycopyrrolate—Dizziness—Epirubicin—bone cancer	0.00165	0.00165	CcSEcCtD
Glycopyrrolate—Pruritus—Doxorubicin—bone cancer	0.00163	0.00163	CcSEcCtD
Glycopyrrolate—Vomiting—Epirubicin—bone cancer	0.00158	0.00158	CcSEcCtD
Glycopyrrolate—Nausea—Methotrexate—bone cancer	0.00158	0.00158	CcSEcCtD
Glycopyrrolate—Rash—Epirubicin—bone cancer	0.00157	0.00157	CcSEcCtD
Glycopyrrolate—Dermatitis—Epirubicin—bone cancer	0.00157	0.00157	CcSEcCtD
Glycopyrrolate—Headache—Epirubicin—bone cancer	0.00156	0.00156	CcSEcCtD
Glycopyrrolate—Dizziness—Doxorubicin—bone cancer	0.00153	0.00153	CcSEcCtD
Glycopyrrolate—Nausea—Epirubicin—bone cancer	0.00148	0.00148	CcSEcCtD
Glycopyrrolate—Vomiting—Doxorubicin—bone cancer	0.00147	0.00147	CcSEcCtD
Glycopyrrolate—Rash—Doxorubicin—bone cancer	0.00145	0.00145	CcSEcCtD
Glycopyrrolate—Dermatitis—Doxorubicin—bone cancer	0.00145	0.00145	CcSEcCtD
Glycopyrrolate—Headache—Doxorubicin—bone cancer	0.00144	0.00144	CcSEcCtD
Glycopyrrolate—Nausea—Doxorubicin—bone cancer	0.00137	0.00137	CcSEcCtD
